Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia

Abstract

Fludarabine and ara-C are an active and relatively safe antileukemic combination in refractory or relapsed ALL. Future studies will incorporate other anti-ALL agents, such as topoisomerase II-reactive drugs, to improve the overall efficacy, and growth factors, to reduce myelosuppression-related complications.